Bradley Pharmaceuticals — Proxy Contest (October 2006)
42 slides from Bradley Pharmaceuticals's proxy contest presentation, Oct 6, 2006
Slide 1: New Horizons, New Accomplishments
New Horizons, New Accomplishments &} BRADLEY PHARMACEUTICALS, INC.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates w
Slide 3: Additional Information
Additional Information In connection with its rescheduled 2006 Annual Meeting of Stockholders, Bradley Pharmaceuticals, Inc. will file a notice of annual meeting and proxy statement with the SEC. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF BRADLEY ARE URGED TO READ THE NOTICE OF ANNUAL MEETIN
Slide 4: Company Overview
Company Overview Specialty pharmaceutical company In-license, develop and bring to market patent-protected pharmaceuticals Create dynamic brands, leveraging core expertise of aggressive, targeted marketing and sales Target specialties include: Dermatology Podiatry Gastroenterology OB/GYN Committed t
Slide 5: Company Overview
Company Overview * As of August 31, 2006 ** Quarter ended June 30, 2006 Dermatologic and Podiatric Brands 126 Sales Representatives* 74.8% of Net Sales** Gastrointestinal, Nutritional and Women’s Health brands 49 Sales Representatives* 25.2% of Net Sales** Authorized Generic Versions of Doak & Kenwo
Slide 6: Major Brands - Doak
Major Brands - Doak Adoxa Zoderm Rosula Solaraze Gel Keralac Carmol 40 Zonalon LidaMantle Total Net Sales by Category for the 6 mos. ended June 30, 2006 as a percent of total Net Sales for the same period Source: Form 10-Q for Quarter Ended June 30, 2006
Slide 7: Major Brands - Kenwood
Major Brands - Kenwood Entsol/ Brontex Deconamine/Tyzine Pamine AnaMantle HC Flora-Q Total Net Sales by Category for the 6 mos. ended June 30, 2006 as a percent of total Net Sales for the same period Source: Form 10-Q for Quarter Ended June 30, 2006 All Others
Slide 8: Company Background
Company Background * As of August 31, 2006 History 1985: Founded by Daniel Glassman, Chairman, President and CEO 1991: Company shares list on the NASDAQ via public offering 2003: Company lists on the NYSE Headquarters Fairfield, New Jersey Employees 311, including 175 sales representatives*
Slide 9: Strategically Expanding From…
Strategically Expanding From… Acquire the rights to products through acquisition and mergers with other specialty pharmaceutical companies Enhance product brands by extending the lifecycle of existing drugs and introducing product line extensions Grow through focused, aggressive marketing and target
Slide 10: Strategically Expanding To…
Strategically Expanding To… Bring to Market patent-protected brands positioned to fill unmet medical needs, and leverage Bradley’s marketing & sales expertise to deliver long-term shareholder value In-License phase II and phase III drugs with long- term intellectual property protection Develop produ
Slide 11: Bradley Financial Snapshot: Net Sales, Full Years
Bradley Financial Snapshot Net Sales – 3 Full Years Millions
Slide 12: Bradley Financial Snapshot: Net Sales 2005 vs. 2006
Bradley Financial Snapshot Net Sales 2005 vs. 2006 Millions
Slide 13: Bradley Financial Snapshot: Net Income, Full Years
Bradley Financial Snapshot Net Income – 3 Full Years Millions
Slide 14: Bradley Financial Snapshot: Net Income 2005 vs. 2006
Bradley Financial Snapshot Net Income - 2005 vs. 2006 * * Includes an R&D expense for the initial payment to MediGene AG of $5.0 million and a share-based compensation charge of $927,000 ** Includes a share-based compensation charge of $922,000. *** Includes a research and development expense for th
Slide 15: Bradley Financial Snapshot: Gross & Operating Profit %
Bradley Financial Snapshot Gross & Operating Profit % – 3 Full Years % % % % % %
Slide 16: Bradley Financial Snapshot: Gross & Operating Profit % 2005 vs. 2006
Bradley Financial Snapshot Gross & Operating Profit % 2005 vs. 2006 * Includes a R&D expense for the initial payment to MediGene AG of $5.0 million and a share-based compensation charge of $927,000 ** Includes a share-based compensation charge of $922,000. *** Includes a research and development exp
Slide 17: Bradley Financial Snapshot: Earnings Per Share, 3 Full Years
Bradley Financial Snapshot Earnings Per Share, Fully Diluted – 3 Full Years * Based on 12,840,000 Diluted Shares ** Based on 18,410,000 Diluted Shares *** Based on 17,950,000 Diluted Shares ** *** *
Slide 18: Bradley Financial Snapshot: Earnings Per Share 2005 vs. 2006
Bradley Financial Snapshot Earnings Per Share, Fully Diluted 2005 vs. 2006 a Based on 18,180,000 Diluted Shares, b Based on 16,500,000 Diluted Shares, c Based on 16,280,000 Diluted Shares, d Based on 16,520,000 Diluted Shares b † e a c d † † f † † † † Includes a R&D expense for the initial payment t
Slide 19: Key Success Factors: Experienced Management Team
Key Success Factors Experienced Management Team VP, Trade/Managed Care Relations William Renzo VP, Chief Scientific Officer Ralph Landau, Ph.D. VP, Corporate Development Alan Goldstein Sr. VP, Sales & Marketing Bradley Glassman VP, Chief Financial Officer Brent Lenczycki Chairman of the Board, Presi
Slide 20: Key Success Factors: Large National Field Force
Key Success Factors * As of 8/31/06 Total Sales Representatives Large National Field Force *
Slide 21: Key Success Factors: Synergistic Promotional Plan/Execution
Key Success Factors Synergistic Promotional Plan/Execution
Slide 22: Foster Dynamic Physician Relationships: Dermatology
Key Success Factors Foster Dynamic Physician Relationships Dermatology Home Office Doctor Program Physician Sample Closet Program Influential Leader Endorsements Relationship Building Programs
Slide 23: Skin Cancer Screening Tour
Key Success Factors Foster Dynamic Physician Relationships Dermatology Skin Cancer Screening Tour Conducted more than 4000 free screenings Generated more than 55 million media impressions about the prevalence of skin cancer and the importance of seeing a dermatologist
Slide 24: Foster Dynamic Physician Relationships: Podiatry and Pharmacists
Key Success Factors Foster Dynamic Physician Relationships Podiatry “See the Podiatrist” Campaign Educational Seminars Major Sponsor, Superbones/Superskin ™ CME Pharmacists “Profiles in Pharmacy” Campaign Leaders in Community Pharmacy Advisory Board Physicians Assistants/Dermatology CME Sponsorship
Slide 25: Foster Dynamic Physician Relationships: Gastroenterology, OB/GYN
Key Success Factors Foster Dynamic Physician Relationships Gastroenterology, Colon Rectal Surgery, OB/GYN’s Home Office Doctor Program Major conference exhibitor Digestive Disease Week American College of Gastroenterology Sponsored more than 61 GE specialty society meetings
Slide 26: Key Success Factors: Lifecycle Management
Key Success Factors Lifecycle Management Introducing new brands and line extensions filling unmet patient and physician needs
Slide 27: Key Success Factors: Lifecycle Management
Key Success Factors Lifecycle Management Introducing new brands and line extensions filling unmet patient and physician needs
Slide 28: Key Success Factors: Clinical Support
Key Success Factors Clinical Support Current and On-going Studies: Zoderm ® : Acne Tolerability/Efficacy (multi-center study) Keralac™ Nail Gel: Dystrophic Nails (Dr. Robbins) Keralac™ Nail Gel: Brittle Nails (Dr. Scher) Solaraze ® Gel: multiple studies
Slide 29: Key Success Factors: Clinical Support
Key Success Factors Clinical Support Current and On-going Studies: Entsol ® : Sinusitis, adjunctive therapy to inhaled steroids Flora-Q ® : IBD, maintenance of remission Flora-Q ® : Treatment of diarrhea predominant IBS
Slide 30: Merger/Acquisition/Co-Marketing Activity
Key Success Factors Merger/Acquisition/Co-Marketing Activity – Last 5 Yrs Merger/Acquisition/Co-Marketing Activity – Prior Company Transact ion Adams Respi ratory ENTSOL® MediGene Polyphenon® E Lundbeck Flora-Q® Company Transact ion Mission Ph armacal AnaMantle HC® Quintiles Bioglan SkyePharma Solar
Slide 31: Expanded Initiatives to Increase Shareholder Value
& BRADLEY PHARMACEUTICALS, INC. SS. Expanded Initiatives to Increase Shareholder Value
Slide 32: Increasing Shareholder Value
Increasing Shareholder Value Pursuing initiatives to enhance long-term shareholder value as part of the Company’s existing strategic plan to: Improve and Expand Product Offerings Strengthen Financial Profile Increase Alignment with Shareholders’ Interests Focus Intensely on Operations
Slide 33: Improve and Expand Product Offerings
Increasing Shareholder Value Improve and Expand Product Offerings In-License phase II and III drugs Develop and bring to market products with long-term intellectual property protection Expand existing partnerships and joint venture relationships Foster new strategic alliances that deliver a stronger
Slide 34: Solaraze Gel
Increasing Shareholder Value Improve and Expand Product Offerings Solaraze Gel Strong brand growth Net Sales for the 2 nd Quarter 2006 for Solaraze have increased 264% since the 1 st Quarter 2005 Current and On-Going Clinical Studies Solaraze ® Gel: AK Extension 1 year tracking multicenter (Dr. Rige
Slide 35: Collaboration with MediGene AG: Polyphenon E
Increasing Shareholder Value * Source: IMS ** Source: MediGene AG Improve and Expand Product Offerings Collaboration with MediGene AG : Polyphenon ® E (PPE) Indication submitted for the treatment of external genital warts and perianal warts caused by human papilloma virus* C o mposition* Ointment fo
Slide 36: Summary of Combined Pivotal Data: As Effective as Aldara
Summary of Combined Pivotal Data Increasing Shareholder Value Source: MediGene AG Improve and Expand Product Offerings PPE Competitive Positioning: As Effective as Aldara ® Clearance rate of baseline warts at least equivalent to Aldara ® Clears newly emerging warts Relatively high clearance in males
Slide 37: Summary of Combined Pivotal Data: Better Safety Profile than Aldara
Summary of Combined Pivotal Data *Aldara ® pivotal data; no head-to-head comparison Increasing Shareholder Value Source: MediGene AG Improve and Expand Product Offerings PPE Competitive Positioning: Better Safety Profile than Aldara ® Systemic side effects unlikely Skin reactions mild Skin reactions
Slide 38: Strengthen Financial Profile
Increasing Shareholder Value Strengthen Financial Profile Continue to remediate all material weaknesses previously disclosed Implement additional Information Technology controls, policies and procedures Financial closing process Created Director of Finance position responsible for overseeing the fin
Slide 39: Increase Alignment with Shareholders' Interests
Increasing Shareholder Value Increase Alignment with Shareholders’ Interests Actively explore initiatives to improve shareholder value Communicate the Company’s existing strategic plan in appropriate forums Participate in industry analyst conferences Conduct quarterly earnings conference calls
Slide 40: Focus Intensely on Operations
Increasing Shareholder Value Focus Intensely on Operations Improve performance across Field Sales Force Establish enhanced goals and actions Improve training and accountability through field operations
Slide 41: Why Bradley Pharmaceuticals
Why Bradley Pharmaceuticals Solid track record of delivering sales and profit growth Strong management team and infrastructure with a core expertise in marketing and sales Strong relationships with key target physician specialties Strategically evolving from lifecycle management to in-licensing & br
Slide 42: New Horizons, New Accomplishments
New Horizons, New Accomplishments &} BRADLEY PHARMACEUTICALS, INC.
Bradley Pharmaceuticals — Proxy Contest (October 2006) on 6ix